

1 **Title:** Estimating post-treatment recurrence after multidrug-resistant tuberculosis  
2 treatment among patients with and without HIV: the impact of assumptions about death and  
3 missing follow-up

4  
5 **Authors:** Sara M. Sauer<sup>1</sup>, Carole D. Mitnick<sup>1</sup>, Uzma Khan<sup>2</sup>, Catherine Hewison<sup>3</sup>, Mathieu  
6 Bastard<sup>4</sup>, David Holtzman<sup>5</sup>, Stephanie Law<sup>1</sup>, Munira Khan<sup>6</sup>, Shrivani Padayachee<sup>6</sup>, Saman  
7 Ahmed<sup>7</sup>, Afshan K. Isani<sup>8</sup>, Aga Krisnanda<sup>9</sup>, Stalz Charles Vilbrun<sup>10</sup>, Sagit Bektasov<sup>11</sup>,  
8 Andargachew Kumsa<sup>12</sup>, Wisney Docteur<sup>13</sup>, Karen Tintaya<sup>14</sup>, Mark McNicol<sup>15</sup>, Hakob  
9 Atshemyan<sup>16</sup>, Tatiana Voynilo<sup>17</sup>, Thin Thin Thwe<sup>18</sup>, Kwonjune Seung<sup>19,20</sup>, Michael Rich<sup>19,20</sup>,  
10 Helena Huerga<sup>4\*</sup>, Palwasha Khan<sup>2,21\*</sup>, Molly Franke<sup>1\*</sup>

11  
12 <sup>1</sup>Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA

13 <sup>2</sup>Interactive Research and Development (IRD) Global, Singapore, Singapore

14 <sup>3</sup>Médecins Sans Frontières, Paris, France

15 <sup>4</sup>Epicentre, Paris, France

16 <sup>5</sup>Partners in Health, Maseru, Lesotho

17 <sup>6</sup>IRD Global, Durban, South Africa

18 <sup>7</sup>IRD Global, Karachi, Pakistan

19 <sup>8</sup>Centers for Disease Control and Prevention, Directorate General Health Services, Sindh, Pakistan

20 <sup>9</sup>IRD Global, Jakarta, Indonesia

21 <sup>10</sup>The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-  
22 Prince, Haiti

23 <sup>11</sup>TB National TB Center, Kazakhstan

24 <sup>12</sup>Ministry of Health, Addis Ababa, Ethiopia

25 <sup>13</sup>Zanmi Lasante, Cange, Haiti

26 <sup>14</sup>Socios en Salud, Lima, Peru

27 <sup>15</sup>Médecins Sans Frontières, Tbilisi, Georgia

28 <sup>16</sup>Médecins Sans Frontières, Yerevan, Armenia

29 <sup>17</sup>Médecins Sans Frontières, Minsk, Belarus

30 <sup>18</sup>Médecins Sans Frontières, Yangon, Myanmar

31 <sup>19</sup>Partners in Health, Boston, USA

32 <sup>20</sup>Brigham and Women's Hospital, Boston, USA

33 <sup>21</sup>Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK

34 \* *Contributed Equally*

35  
36  
37 **Key words:** competing events, inverse-probability weighting, missing follow-up, MDR-TB,  
38 post-treatment recurrence

44 **ABSTRACT**

45 **Background:** Quantification of recurrence risk following successful treatment is crucial to  
46 evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB).  
47 However, such analyses are complicated when some patients die or become lost during post-  
48 treatment-follow-up.

49 **Methods:** We analyzed data on 1,991 patients who successfully completed a longer MDR/RR-  
50 TB regimen containing bedaquiline and/or delamanid between 2015 and 2018 in 16 countries.  
51 Using five approaches for handling post-treatment deaths, we estimated the six-month post-  
52 treatment TB recurrence risk overall, and by HIV status. We used inverse-probability-weighting  
53 to account for patients with missing follow-up and investigated the impact of potential bias from  
54 excluding these patients without applying inverse-probability weights.

55 **Results:** The estimated TB recurrence risk was 6.6 per 1000 (95% confidence interval  
56 (CI):3.2,11.2) when deaths were handled as non-recurrences, and 6.7 per 1000 (95% CI:2.8,12.2)  
57 when deaths were censored and inverse-probability weights were applied to account for the  
58 excluded deaths. The estimated risk of composite recurrence outcomes were 24.2 (95%  
59 CI:14.1,37.0), 10.5 (95% CI:5.6,16.6), and 7.8 (95% CI:3.9,13.2) per 1000 for recurrence or 1)  
60 any death, 2) death with unknown or TB-related cause, 3) TB-related death, respectively.  
61 Corresponding relative risks for HIV status varied in direction and magnitude. Exclusion of  
62 patients with missing follow-up without inverse-probability-weighting had a small but apparent  
63 impact on estimates.

64  
65 **Conclusion:** The estimated six-month TB recurrence risk was low, and the association with HIV  
66 status was inconclusive due to few recurrence events. Estimation of post-treatment recurrence  
67 will be enhanced by explicit assumptions about deaths and appropriate adjustment for missing  
68 follow-up data.

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

## 85 **BACKGROUND:**

86 Quantifying post-treatment tuberculosis (TB) recurrence is critical to evaluating the effectiveness  
87 of all multidrug- and rifampicin-resistant (MDR/RR) TB regimens during routine care.  
88 Estimating risk of recurrence is complicated, however, when some patients die or are missing  
89 data during the post-treatment follow-up (FU) period. Post-treatment deaths that are unrelated to  
90 TB preclude recurrence and constitute *competing* [1-3] or *intercurrent* [4] events. Conversely, if  
91 deaths occur due to undetected TB, the risk of recurrence can be underestimated. In analyses of  
92 recurrence, assumptions are made regarding post-treatment deaths; different assumptions alter  
93 the estimated quantity and the resulting interpretation [1]. Prior studies have typically 1)  
94 excluded patients who died [5-8], which will bias the estimated risk of recurrence in the likely  
95 scenario that people who do and do not die have different underlying risks of TB recurrence; 2)  
96 effectively assumed that none of the post-treatment deaths were due to recurrent TB [9-10],  
97 which is not supported by the literature [11-13]; or 3) omitted details on how deaths were  
98 analyzed [14-18], which prevents a clear interpretation of the resulting estimate.

99 Analytic challenges also arise from patients for whom there is no post-treatment follow-up data.  
100 In these patients, it is unknown whether recurrent TB occurred. Most prior studies that estimate  
101 TB recurrence have excluded individuals who lack post-treatment follow-up [5-7]. Valid  
102 estimates under this approach require that individuals who do and do not have post-treatment  
103 follow-up have a similar underlying risk of recurrent TB. If, on the other hand, there are common  
104 causes of recurrence and lack of post-treatment follow-up, this assumption does not hold, and  
105 simply excluding individuals who lack follow-up data may lead to selection bias [19-20].

106 In this paper we estimated the overall risk of TB recurrence within six months of successful  
107 MDR/RR-TB treatment with a longer regimen containing bedaquiline (BDQ) and/or delamanid  
108 (DLM) and compared this risk among those with and without HIV infection. Compared to  
109 people without HIV, those with HIV are more susceptible to TB disease [21], at increased risk of  
110 MDR-TB [22], more prone to serious adverse events [23], and at higher risk of unfavorable  
111 treatment outcomes, including recurrence [24-25]. In our analyses, we examined multiple  
112 approaches for handling post-treatment deaths or adjustment for potential bias due to exclusion  
113 of missing follow-up data and assessed whether results were sensitive to the approach chosen.

## 114 **METHODS**

### 115 *Data source and study population.*

116 We used data from the endTB Observational Study, a prospective cohort of 2,788 individuals  
117 who initiated a longer individualized MDR/RR-TB regimen containing BDQ and/or DLM  
118 between 2015 and 2018 in one of seventeen countries (Armenia, Bangladesh, Belarus, Ethiopia,  
119 Georgia, Haiti, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Lesotho, Myanmar, North Korea,  
120 Pakistan, Peru, South Africa, Vietnam) on five continents [26]. For this analysis, we included  
121 patients' first treatment in endTB, excluded those with confirmed sensitivity to rifampicin and  
122 restricted to patients with end of treatment success, defined as cure or treatment completion. We  
123 additionally excluded all individuals from North Korea, as post-treatment follow-up was not  
124 conducted at this site.

125

126 ***Outcome measure.***

127 The outcome of interest was a binary indicator of TB recurrence, irrespective of whether it was  
128 reinfection with a new strain of *Mycobacterium tuberculosis* or relapse with the initial infecting  
129 strain, within six months of successful treatment. Across participating sites, post-treatment  
130 outcomes and culture results were recorded by clinicians on a standardized form at scheduled  
131 visits six months post-treatment. These post-treatment outcomes were classified into the  
132 following categories: no change, post-treatment death, recurrent TB, lost to follow-up (LTFU),  
133 and not evaluated. We grouped individuals with the latter two outcomes, or for whom there was  
134 no post-treatment outcome form, into a single ‘missing FU’ category.

135

136 ***Statistical methods.***

137 Addressing post-treatment deaths. We considered five strategies from the competing/intercurrent  
138 events literature for handling deaths that occurred within six months post-treatment (Table 1,  
139 Figure 1).

140

141 First, in what we term the *observed recurrence* strategy, we included patients who died but did  
142 not count them as recurrences, thereby assuming that patients who died did *not* experience  
143 recurrent TB. Second, in the *hypothetical recurrence* strategy [1-4], we excluded patients who  
144 died and applied stabilized inverse-probability (IP) weights to account for potentially different  
145 underlying risks of recurrent TB among excluded vs included patients. This strategy posits a  
146 hypothetical scenario in which all deaths were prevented, so that whether these (in reality  
147 deceased) patients experienced recurrent TB within six months was observed. Factors associated  
148 with both post-treatment death and post-treatment recurrence were used in the IP weight  
149 construction, namely age, CD4 count, cavitory disease, alcohol use, drug use, smoking,  
150 incarceration, diabetes, stoppage of group A drugs (BDQ, fluoroquinolones, linezolid) due to  
151 adverse events, and BMI (see Supporting Information for details on weight construction).

152

153 In strategies 3 through 5, we defined various composite outcomes of recurrence or death. In the  
154 *observed composite/any* strategy, we included recurrent TB and death from any cause in the  
155 outcome, while in the *observed composite/probable* strategy, we included recurrent TB and death  
156 with unknown or TB-related cause. Finally, in the *observed composite/explicit* strategy, we  
157 included recurrent TB and only death due to a TB-related cause in the outcome. In the latter two  
158 composite outcome strategies, we included any deaths not counted in the outcome as non-  
159 recurrences, thereby assuming that these patients did not experience recurrent TB.

160

161 Addressing missing post-treatment follow-up data. We utilized stabilized IP weights to overcome  
162 the potential selection bias induced by excluding patients who lack follow-up data [19-20]. We  
163 constructed the weight denominators by estimating the probabilities of having an observed six  
164 month post-treatment outcome conditional on HIV status and joint predictors of missing FU and  
165 recurrent TB: cavitory disease, BMI, time to culture conversion, use and duration of Group A  
166 drugs, stoppage of Group A drugs due to an adverse event, likely effectiveness of Group A drugs,  
167 country of treatment site, and diabetes. See Supporting Information for details.

168

169 Estimating post-treatment recurrence. We computed estimates of recurrent TB risk, overall and  
170 by HIV status, by fitting an IP-weighted logistic regression model with the HIV status indicator  
171 as the only covariate. Weights to account for missing FU were included in all analyses, whereas

172 weights to account for common causes of death and recurrent TB were only employed in the  
173 *hypothetical recurrence* analysis, in which new overall weights were constructed by multiplying  
174 together the sets of weights. Furthermore, we incorporated an additional set of IP weights in all  
175 analyses to adjust for potential confounding by the common causes of HIV status and recurrent  
176 TB, in this case age, country of treatment site, hepatitis C, alcohol use, drug use, smoking, and  
177 incarceration (see Supporting Information). We constructed 95% credible intervals for all  
178 estimates with a bootstrapping approach [27] using the `boot` package in R.

179  
180 Sensitivity analysis. We conducted a sensitivity analysis to explore how the results from a  
181 common strategy for handling missing post-treatment follow-up data [5-7] compared to those  
182 from the IP-weighting approach. In particular, we repeated the analysis described in the previous  
183 section, this time without applying IP weights, thereby imposing the assumption that people with  
184 and without FU are similar on average with regard to factors that influence recurrence. This  
185 approach does not account for the potential selection bias induced by excluding patients who  
186 lack FU data

187  
188 Simulation Study. Finally, to investigate the impact of potential selection bias in a different data  
189 setting, we conducted a simulation study (see Supporting Information). Briefly, we generated an  
190 underlying population in which cavitory disease is strongly associated with having missing FU,  
191 TB recurrence, and death. We then computed and compared estimates of overall TB recurrence  
192 risk with and without adjustment for potential selection bias, i.e., with and without weights to  
193 account for joint predictors of missing FU and TB recurrence. We investigated the impact on  
194 results of varying different characteristics of the baseline simulation scenario, such as the  
195 underlying risk of TB recurrence.

## 196 197 **RESULTS**

198 Of the 2,762 patients with confirmed RR/MDR-TB who initiated a longer individualized  
199 regimen containing BDQ and/or DLM, 2,053 (74.3%) patients were cured or completed  
200 treatment (Figure 2). After removing patients from North Korea, the final dataset we analyzed  
201 contained 1,991 patients. Among these individuals, 17 (0.9%) died within six-months post-  
202 treatment, 746 (37.5%) lacked post-treatment follow-up data, and 1228 (61.7%) had an observed  
203 six-month post treatment-outcome of no change or recurrence.

204  
205 Table 2 shows the characteristics of the 1,991 patients, overall and by six-month post-treatment  
206 outcome. Overall, 11.9% of patients were living with HIV; 21.4% of those who lacked six-month  
207 follow-up data and 11.8% of those who died post-treatment had HIV coinfection. The overall  
208 patient age distribution was similar to that among patients who were missing FU data or were  
209 observed at six-months post-treatment, while patients who died were more likely to be aged 60  
210 or older. Compared to patients with follow-up data, patients who lacked follow-up data were  
211 more likely to have a body mass index <18.5 and were less likely to have diabetes. The rate of  
212 post-treatment deaths and missing follow-up was variable across sites.

213  
214 ***Six-month risk of TB recurrence.*** Ten patients (0.5%) experienced recurrent TB within six-  
215 months post-treatment with a median time to recurrence of 161 days. Table 3 shows the  
216 estimated six-month risk of recurrent TB under the five strategies for handling post-treatment  
217 deaths. The risk of recurrent TB was 6.6 (95% credible interval [CI]: 3.2, 11.2) per 1000

218 individuals under the *observed recurrence* strategy, and 6.7 (95% CI: 2.8, 12.2) per 1000 under  
219 the *hypothetical recurrence* strategy. The estimated frequencies of a composite outcome under  
220 the *observed composite/any*, *observed composite/probable*, and *observed composite/explicit*  
221 strategies were 24.2 (95% CI: 14.1, 37.0), 10.5 (95% CI: 5.6, 16.6), and 7.8 (95% CI: 3.9, 13.2)  
222 per 1000, respectively.

223  
224 **Risk of TB recurrence by HIV status.** The relative risk of recurrent TB in patients with and  
225 without HIV under the *observed recurrence* and *hypothetical recurrence* strategies were 1.46  
226 (95% CI: 0.31, 7.08) and 1.42 (95% CI: 0.30, 7.14), respectively (Table 3). In both cases, relative  
227 risks were above one, suggesting a higher risk of recurrence among patients living with HIV;  
228 however, confidence intervals were wide. The corresponding risk ratios for the three composite  
229 outcomes were 0.62 (95% CI: 0.12, 2.01), 0.85 (95% CI: 0.20, 3.86), and 1.20 (95% CI: 0.25,  
230 5.73) for the respectively *observed composite/any*, *observed composite/probable*, and *observed*  
231 *composite/explicit* strategies, respectively.

232  
233 **Sensitivity analysis.** When patients missing post-treatment follow-up were excluded from the  
234 analysis without adjustment for potential selection bias, the estimated risk of recurrent TB  
235 overall was 7.5 per 1000 (95% CI: 3.9, 11.2) under the *observed recurrence* strategy, 7.5 per  
236 (95% CI: 3.1, 11.8) under the *hypothetical recurrence* strategy and 20.2 (95% CI: 13.1, 29.3),  
237 11.9 (95% CI: 6.6, 18.3), and 9.1 (95% CI: 4.8, 15.4) per 1000 under the three composite  
238 strategies (Table 4).

239  
240 The impact of potential selection bias was more apparent when looking at estimates of relative  
241 risk by HIV status. When results were not adjusted for selection bias, the point estimates differed  
242 from the adjusted estimates in terms of magnitude, and in some cases, direction (Table 4).

243  
244 **Simulation study.** The results of the simulation study are shown in Table S3-S9 of the  
245 Supporting Information. The variation in results across simulation scenarios demonstrates that  
246 there are several factors that increase the impact of selection bias, such as a stronger relationship  
247 between the joint predictor(s) of missing FU and recurrence and 1) missing FU or 2) recurrence.

248  
249

## 250 DISCUSSION

251 The overall risk of TB recurrence, or risk of TB recurrence or death, was low in this population,  
252 substantiating the effectiveness of longer MDR-TB regimens containing BDQ and/or DLM. This  
253 was true irrespective of method used to handle post-treatment deaths. The association between  
254 HIV and TB recurrence was inconclusive due to the small number of recurrences and deaths,  
255 which resulted in wide confidence intervals across all strategies.

256  
257 The estimates of TB recurrence and relative risk comparing patients with and without HIV  
258 were similar whether derived under the assumption that patients who died post-treatment did not  
259 experience recurrent TB (*observed recurrence*) or in a hypothetical scenario where all patient  
260 deaths could have been prevented (*hypothetical recurrence*). There are other settings in which  
261 the difference between these two strategies might be more pronounced; for example, if post-  
262 treatment deaths were more common and patients who died had a much higher risk of recurrent

263 TB compared to patients who did not, then the *hypothetical recurrence* estimate would be  
264 markedly higher than the *observed recurrence* estimate.

265  
266 As expected, estimates of the six-month incidence of composite outcomes of TB recurrence or  
267 death were higher than the estimates for recurrence alone. Furthermore, estimates varied widely  
268 depending on which deaths were included in the composite outcome: the incidence of recurrent  
269 TB or death from any cause was twice that of recurrent TB or TB-related death, and the risk ratio  
270 estimate changed direction depending on whether deaths of unknown cause were included in the  
271 outcome or assumed to be non-recurrences. The proportion of post-treatment deaths that are  
272 related to TB, and therefore, the importance of incorporating cause of death into composite  
273 estimates, will vary by setting and highlights the importance of ascertaining and recording such  
274 information.

275  
276 The estimates from each strategy answer different questions and in practice, researchers will  
277 need to select which one to report [1-4]. Intuitively, the *observed recurrence* strategy may be  
278 preferred to the *hypothetical recurrence* strategy, as the latter considers a scenario that is  
279 aspirational but not currently relevant to most settings (i.e., one in which all post-treatment  
280 deaths could be prevented). On the other hand, the *observed recurrence* strategy may be  
281 inadequate in certain circumstances. For example, if patients with a certain characteristic were  
282 much more likely to die post-treatment compared to those without that characteristic, the  
283 *observed recurrence* estimate could indicate that patients with the characteristics are less likely  
284 to experience recurrent TB just because earlier death largely prevented this group from  
285 developing recurrent TB; see Rojas-Saunero et. al [2] for another example of this. A second  
286 scenario in which the *observed recurrence* strategy may not be ideal is when deaths due to  
287 undetected TB are common. In this case, one of the composite strategies might be preferable,  
288 particularly when complete information on cause of death is available. One potential drawback  
289 of the composite strategies is that they change the outcome of interest, which may not always be  
290 of scientific interest.

291  
292 Patients with low BMI or HIV were more likely, and patients with diabetes were less likely, to  
293 have missing FU data in this study. Previous studies have linked each of these subgroups to an  
294 increased risk of recurrent TB [8,10,17], which underscores the importance of accounting for  
295 patients with missing FU data when estimating recurrent TB. In our sensitivity analysis, the  
296 estimates that were computed by excluding patients with missing FU data but without accounting  
297 for selection bias through IP-weighting were similar to the IP-weighted estimates of overall  
298 recurrence. The differences in the weighted and unweighted relative risk estimates were more  
299 pronounced, though wide confidence intervals resulted in the same conclusion. This will not  
300 always be the case: larger imbalances in the characteristics of patients with and without FU  
301 combined with a stronger association of these characteristics with TB recurrence risk would  
302 result in a greater impact of selection bias, and consequently larger differences in the weighted  
303 and unweighted estimates. The simulation study of the Supporting Information provides  
304 examples of several such settings.

305  
306 This study has several limitations. First, we were not able to distinguish between TB relapse and  
307 reinfection. While the rate of reinfection will vary by setting, we sought to limit misclassification  
308 by estimating the six-month incidence, a time during which relapse is likely to be the prevailing

309 source of recurrent TB [28]. Second, we considered a less informative binary outcome rather  
310 than a time to event outcome [6], as follow-up was only consistently reported using a six-month  
311 post-treatment form at most sites rather than through continuous follow-up. Third, our results on  
312 HIV as a determinant of recurrence may be affected by collider bias [29-30]. This could occur if  
313 there is a factor such as age that is associated with both HIV status and inclusion in the cohort. If  
314 a third factor, such as TB disease severity, is associated with cohort inclusion and recurrent TB  
315 risk, the relationship observed between HIV status and recurrent TB may be distorted. This is a  
316 challenge with all observational TB studies, as TB is more likely to go undetected among people  
317 living with HIV [31]. Therefore, this group is less likely to be included in a treatment cohort .  
318 This bias could be reduced through IP-weighting if data were available on factors related to 1) to  
319 HIV status and cohort inclusion and 2) cohort inclusion and experiencing post-treatment TB  
320 recurrence. Unfortunately, this information is often unattainable in practice, as it requires being  
321 able to identify all people living with HIV who are eligible for MDR-TB treatment.

322 As multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) treatment guidelines evolve  
323 in response to emerging evidence [32-34] on the relative safety and effectiveness of all-oral  
324 shortened regimens compared to conventional longer treatments, an important and currently  
325 unanswered question is whether the relative safety and effectiveness of shortened vs longer  
326 regimens differ across important patient subgroups, such as people living with HIV [35].  
327 Rigorous analyses of post-TB treatment recurrence are needed to accurately understand whether  
328 certain groups may require closer monitoring, given possible increased risk of relapse [36-38]  
329 relative to longer regimens. While methods for handling competing events and potential  
330 selection bias due to losses to follow-up are well-established [4, 19-20], their use in the context  
331 of estimating TB recurrence is sparse. Careful handling of post-treatment deaths and missing  
332 post-treatment follow-up data together with accompanying sensitivity analyses will generate  
333 evidence that is more robust and interpretable, with the overall goal of improving treatment and  
334 care.

335 **Funding.** The endTB observational study was funded by UNITAID. SMS was supported by the  
336 National Institutes of Allergy and Infectious Diseases under Award Number T32 AI007433.  
337 MFF, CDM, KS, and MR were supported by the National Institutes of Allergy and Infectious  
338 Diseases under Award Number R01AI46095. The funders had no role in the conceptualization,  
339 analysis, or presentation of findings of this study.

340 **Acknowledgements.** The authors thank the patients who participated in the endTB  
341 Observational Study and the clinicians and program staff of participating national tuberculosis  
342 programs. They also thank the endTB staff at Partners in Health, Doctors Without Borders,  
343 Epicentre, and Interactive Research and Development.

344  
345 **Author contributions.** SMS, CDM, and MF led the conceptualization, data curation,  
346 methodology, analysis, and writing of the paper. CDM, MF, MR, KS, UK, PK MB, CH, and HH  
347 led the design of the endTB study. UK, CH, MB, DH, SL, MK, SP, SA, AKI, A Krisnanda,  
348 SCV, SB, A Kumsa, WD, KT, MM, HA, TV, TTT, KS, MR, HH, and PK contributed to data  
349 collection and curation. All authors contributed to editing and review of the paper.

350



351 **Data availability statement.** Some of the data included in this analysis are managed in countries  
352 governed by the European Union General Data Protection Regulation (GDPR). The data contain  
353 sensitive and potentially identifying information and cannot be sufficiently anonymized to meet  
354 GDPR standards and retain their utility. Pseudo-anonymized data will be made available upon  
355 request to an MSF Medical Director at [endTB.ClinicalTrial@paris.msf.org](mailto:endTB.ClinicalTrial@paris.msf.org), and execution of a  
356 data sharing agreement or alternate means that allows assurance that principles of GDPR  
357 regulations will be met.

358  
359 **Conflict of interest.** CDM has served as a board member of Otsuka Scientific Advisory Board.  
360 All other authors report no potential conflicts.

## 361 **References**

- 363 1. Young JG, Stensrud MJ, Tchetgen Tchetgen EJ, et al. "A causal framework for classical  
364 statistical estimands in failure-time settings with competing events." *Statistics in*  
365 *Medicine*. 2020; 39(8):1199-1236. doi:10.1002/sim.8471
- 366 2. Rojas-Saunero PL, Young JG, Didelez V, et al. "Choosing questions before methods in  
367 dementia research with competing events and causal goals." *American Journal of*  
368 *Epidemiology*. 2023. doi:10.1093/aje/kwad090
- 369 3. Chiu YH, Stensrud MJ, Dahabreh IJ, et al. "The effect of prenatal treatments on offspring  
370 events in the presence of competing events: an application to a randomized trial of  
371 fertility therapies." *Epidemiology*. 2020; 31(5):636-643. doi:  
372 10.1097/EDE.0000000000001222
- 373 4. Pham TM, Tweed CD, Carpenter DR, et al. "Rethinking intercurrent events in defining  
374 estimands for tuberculosis trials." *Clinical Trials*. 2022; 19(5): 522-533. doi:  
375 10.1177/17407745221103853
- 376 5. Franke MF, Appleton SC, Mitnick CD, et al. "Aggressive regimens for multidrug-  
377 resistant tuberculosis reduce recurrence." *Clinical Infectious Diseases*. 2013; 56(6): 770-  
378 776. doi:10.1093/cid/cis1008
- 379 6. Becerra MC, Appleton SC, Franke MF, et al. "Recurrence after treatment for pulmonary  
380 multidrug-resistant tuberculosis." *Clinical Infectious Diseases*. 2010; 51(6): 709–11. doi:  
381 10.1086/655892
- 382 7. Schwöbel V, Trébuçq A, Kashongwe Z, et al. "Outcomes of a nine-month regimen for  
383 rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine  
384 African countries." *EClinicalMedicine*. 2020; 20: 100268. doi:  
385 10.1016/j.eclinm.2020.100268.
- 386 8. Chiang CY, Enarson DA, Yu MC, et al. "Outcome of pulmonary multidrug-resistant  
387 tuberculosis: a 6-yr follow-up study." *European Respiratory Journal*. 2006; 28:980–985.  
388 doi: 10.1183/09031936.06.00125705
- 389 9. Kim DH, Kim HJ, Park SK, et al. "Treatment outcomes and long-term survival in  
390 patients with extensively drug-resistant tuberculosis". *American Journal of Respiratory*  
391 *and Critical Care Medicine*." 2008; 178(10):1075–1082. doi: 10.1164/rccm.200801-  
392 1320C
- 393 10. Shin SS, Furin JJ, Alcántara F, et al. "Long-term follow-up for multidrug-resistant  
394 tuberculosis." *Emerging Infectious Diseases*. 2006; 12(4):687–688. doi:  
395 10.3201/eid1204.041256


- 396 11. Mathema B, Kurepina NE, Bifani PJ, et al. “Molecular epidemiology of tuberculosis:  
397 Current insights.” *Clinical Microbiology Reviews*. 2006;19(4):658-685. doi:  
398 10.1128/CMR.00061-05
- 399 12. Panjabi R, Comstock GW, Golub JE. “Recurrent tuberculosis and its risk factors:  
400 Adequately treated patients are still at high risk.” *The International Journal of*  
401 *Tuberculosis and Lung Disease*. 2007;11(8):828-837.
- 402 13. Takarinda KC, Sandy C, Masuka N, et al. “Factors associated with mortality among  
403 patients on TB treatment in the southern region of Zimbabwe.” *Tuberculosis Research*  
404 *and Treatment*. 2017. doi: 10.1155/2017/6232071
- 405 14. Khan FA, Gelmanova IY, Franke MF, et. al. “Aggressive regimens reduce risk of  
406 recurrence after successful treatment of MDR-TB.” *Clinical Infectious Diseases*. 2016;  
407 63(2): 214-220. doi: 10.1093/cid/ciw276.
- 408 15. Lee J, Lim HJ, Cho YJ, et al. “Recurrence after successful treatment among patients with  
409 multidrug-resistant tuberculosis.” *International Journal of Tuberculosis and Lung*  
410 *Disease*. 2011; 15(10): 1331–1333. doi: 10.5588/ijtld.11.0098
- 411 16. Cavanaugh JS, Kazenny BY, Nguyen ML, et al. “Outcomes and follow-up of patients  
412 treated for multidrug-resistant tuberculosis in Orel, Russia, 2002–2005.” *International*  
413 *Journal of Tuberculosis and Lung Disease*. 2012; 16(8): 1069–1074. doi:  
414 10.5588/ijtld.11.0696
- 415 17. Leung EC, Yew WW, Leung CC, et al. “Shorter treatment duration for selected patients  
416 with multidrug-resistant tuberculosis.” *European Respiratory Journal*. 2011; 38: 227–  
417 230. doi: 10.1183/09031936.00186310
- 418 18. Aung KJ, Van Deun A, Declercq E, et al. “Successful ‘9-month Bangladesh regimen’ for  
419 multidrug-resistant tuberculosis among over 500 consecutive patients.” *International*  
420 *Journal of Tuberculosis and Lung Disease*. 2014; 18(10): 1180–1187. doi:  
421 10.5588/ijtld.14.0100
- 422 19. Hernán MA, Hernández-Díaz S, Robins JM. “A structural approach to selection bias.  
423 Epidemiology.” 2004; 15(5): 615-625. doi:  
424 20. Hernán MA, Robins JM. “Chapter 8: Selection Bias.” *Causal Inference: What If*. 2020.  
425 Boca Raton: Chapman & Hall/CRC.
- 426 21. World Health Organization. “Global Tuberculosis Report.” 2022. Available at:  
427 [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)  
428 [tuberculosis- report-2022](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)
- 429 22. Sultana ZZ, Hoque FU, Beyene J, et al. “HIV infection and multidrug resistant  
430 tuberculosis: a systematic review and meta-analysis.” *BMC Infectious Diseases*. 2021;  
431 21(1): 1-13. doi: 10.1186/s12879-020- 05749-2
- 432 23. Hong H, Budhathoki C, Farley JE. “Increased risk of aminoglycoside-induced hearing  
433 loss in MDR-TB patients with HIV coinfection.” *International Journal of Tuberculosis*  
434 *and Lung Disease*. 2018; 22(6): 667-674. doi: 10.5588/ijtld.17.0830
- 435 24. Loveday M, Reuter A, Furin J, et al. “The STREAM trial: missed opportunities and  
436 lessons for future clinical trials.” *Lancet Infectious Diseases*. 2019; 19(4): 351- 353. doi:  
437 10.1016/S1473-3099(19)30106-9
- 438 25. Imperial MZ, Nahid P, Phillips PPJ, et al. “A patient-level pooled analysis of treatment  
439 shortening regimens for drug-susceptible pulmonary tuberculosis.” *Nature Medicine*.  
440 2018; 24: 1708–1715. doi: 10.1038/s41591-018-0224-2

- 441 26. Khan U, Huerga H, Khan AJ, et al. “The endTB (Expand New Drugs for TB)  
442 Observational Study Protocol: Treatment of MDR-TB with bedaquiline or delamanid  
443 containing regimens.” *BMC Infectious Diseases*. 2019; 19(1): 1-9. doi: 10.1186/s12879-  
444 019-4378-4
- 445 27. Davison AC and Hinkley DV. *Bootstrap Methods and Their Application*. 1997.  
446 Cambridge University Press.
- 447 28. Marx FM, Dunbar R, Enarson DA, et al. "The temporal dynamics of relapse and  
448 reinfection tuberculosis after successful treatment: a retrospective cohort study." *Clinical*  
449 *Infectious Diseases*. 2014; 58(12): 1676-1683. doi: 10.1093/cid/ciu186
- 450 29. Cole SR, Platt RW, Schisterman EF, et al. "Illustrating bias due to conditioning on a  
451 collider." *International Journal of Epidemiology*. 2010; 39: 417–420. doi:  
452 10.1093/ije/dyp334
- 453 30. Elwert F and Winship C. “Endogenous selection bias: the problem of conditioning on a  
454 collider variable.” *Annual Review of Sociology*. 2014; 40: 31–53. doi: 10.1146/annurev-  
455 soc-071913-043455
- 456 31. Mntonintshi M, Mabunda S, Namugenyi KAF, et al. “Undiagnosed tuberculosis in  
457 patients with HIV infection who present with severe anaemia at a district hospital.”  
458 *African Journal Primary Health Care and Family Medicine*. 2017; 9(1): 1-6. doi:  
459 10.4102/phcfm.v9i1.1406
- 460 32. Solans BP, Imperial MZ, and Olugbosi M, et al. "Analysis of dynamic efficacy endpoints  
461 of the Nix-TB trial." *Clinical Infectious Diseases*. 2023; doi: 10.1093/cid/ciad051
- 462 33. Nyang’wa BT, Berry C, Kazounis E, et al. "A 24-week, all-oral regimen for rifampin-  
463 resistant tuberculosis." *New England Journal of Medicine*. 2022; 387(25): 2331-2343.  
464 doi: 10.1056/NEJMoa2117166
- 465 34. Goodall RL, Meredith SK, Nunn AJ, et al. "Evaluation of two short standardised  
466 regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an  
467 open-label, multicentre, randomised, non-inferiority trial." *The Lancet*.  
468 2022; 400(10366): 1858-1868. doi: 10.1016/S0140-6736(22)02078-5
- 469 35. World Health Organization. “WHO consolidated guidelines on tuberculosis: module 4:  
470 treatment: drug-resistant tuberculosis treatment.” 2022. Available at:  
471 <https://www.who.int/publications/i/item/9789240063129>
- 472 36. Merle CS, Fielding K, Sow OB, et al. “A Four-month gatifloxacin-containing regimen for  
473 treating tuberculosis.” *New England Journal of Medicine*. 2014; 371(17): 1588-1598.  
474 doi:10.1056/NEJMoa1315817.
- 475 37. Jindani A, Harrison TS, Nunn AJ, et al. “High-dose rifapentine with moxifloxacin for  
476 pulmonary tuberculosis.” *New England Journal of Medicine*. 2014; 371(17): 1599-1608.  
477 doi: 10.1056/NEJMoa1314210.
- 478 38. Gillespie SH, Crook AM, McHugh TD, et al. “Four-month moxifloxacin-based regimens  
479 for drug-sensitive tuberculosis.” *New England Journal of Medicine*. 2014; 371(17): 1577-  
480 1587. doi:10.1056/NEJMoa1407426.

481  
482


483

484 **Figure 1:** Graphical representation of the association between HIV and recurrent TB at six  
 485 months post-treatment. The *observed recurrence* strategy estimates paths *a* and *b-c*; the  
 486 *hypothetical recurrence* strategy estimates path *a* only, adjusting for common causes of death  
 487 within six months post-treatment (prior to recurrence) and recurrent TB ( $L_1$ ) to eliminate bias  
 488 through the *b-d-e* path; adjustment for the joint predictors of missing FU ( $L_2$ ) accounts for  
 489 potential selection bias through the *f-g-h* path; adjustment for common causes of HIV infection  
 490 and recurrent TB ( $L_3$ ) addresses potential confounding bias by blocking the *i-j* path.  
 491



492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511

512 **Figure 2:** Inclusion/exclusion criteria for the post-treatment analysis



535 **Table 1:** Strategies for handling deaths post-treatment

Approach	Operationalization	Assumptions
<b>Observed recurrence</b> <sup>1</sup>	Include individuals who died in the analysis and treat as non-recurrences <sup>4</sup>	Patients who died did <i>not</i> experience recurrent TB
<b>Hypothetical recurrence</b> <sup>2</sup>	Censor (exclude) individuals who died, account for common causes of death and recurrence with IP weights	All common causes of death and recurrence have been accounted for
<b>Observed composite/any</b> <sup>3</sup>	Define a composite outcome of recurrence or death from <i>any</i> cause	
<b>Observed composite/probable</b> <sup>3</sup>	Define a composite outcome of recurrence or death with either 1) unknown cause, 2) cause related to TB; treat deaths with cause unrelated to TB as non-recurrences <sup>4</sup>	Patients with deaths unrelated to TB did <i>not</i> experience recurrent TB
<b>Observed composite/explicit</b> <sup>3</sup>	Define a composite outcome of recurrence or death with cause related to TB, treat deaths with 1) unknown cause and 2) cause unrelated to TB as non-recurrences <sup>4</sup>	Patients with deaths of unknown cause or cause unrelated to TB did <i>not</i> experience recurrent TB

536 <sup>1</sup>when estimating the association between HIV and post-treatment recurrence, the *observed recurrence* strategy  
 537 corresponds to estimating the *total effect* of HIV in the causal inference with competing events literature [1-3]

538 <sup>2</sup>in the causal inference literature, the quantity estimated through the hypothetical recurrence strategy is known as  
 539 the *controlled direct effect* [1-3]; in the intercurrent events literature, the corresponding strategy is called the  
 540 *hypothetical* strategy [4]

541 <sup>3</sup>composite strategies correspond to estimating the *total effect on a composite event* in the causal inference literature  
 542 [1-3], and as the *composite* strategy in the corresponding intercurrent events literature [4]

543 <sup>4</sup>recurrent TB outcome indicator set to 0 for all patients handled as non-recurrences

544

545

546

547

548

549  
550

**Table 2:** Summary of patient characteristics by six-month post-treatment outcome.

<b>Characteristic</b>	<b>Overall (%) n=1991</b>	<b>Observed (%) n=1228</b>	<b>LTFU (%) n=746</b>	<b>Died (%) n=17</b>
<b>HIV</b>				
Yes	237 (11.9)	75 (6.1)	160 (21.4)	2 (11.8)
No	1754 (88.1)	1153 (93.9)	586 (80.2)	15 (88.2)
<b>Age</b>				
0-19	161 (8.1)	87 (7.1)	73 (9.8)	1 (5.9)
20-44	1296 (65.1)	814 (66.3)	474 (63.5)	8 (47.1)
45-59	435 (21.8)	274 (22.3)	157 (21.0)	4 (23.5)
60+	99 (5.0)	53 (4.3)	42 (5.6)	4 (23.5)
<b>BMI &lt;18.5kg</b>				
Yes	423 (21.2)	215 (17.5)	197 (26.4)	11 (64.7)
No	1568 (78.8)	1013 (82.5)	549 (73.6)	6 (35.3)
<b>Diabetes mellitus</b>				
Yes	295 (14.8)	189 (15.4)	103 (13.8)	3 (17.6)
No	1669 (83.8)	1031 (84.0)	624 (83.6)	14 (82.4)
Missing	27 (1.4)	8 (0.7)	19 (2.5)	0 (0.0)
<b>Hepatitis C</b>				
Yes	185 (9.3)	130 (10.6)	53 (7.1)	2 (11.8)
No	1806 (90.7)	1098 (89.4)	693 (92.9)	15 (88.2)
<b>Cavitory disease</b>				
Yes	682 (34.3)	436 (35.5)	239 (32.06)	7 (41.2)
No	1197 (60.1)	756 (61.6)	432 (57.9)	9 (52.9)
Missing	112 (5.6)	36 (2.9)	75 (10.1)	1 (5.9)
<b>BDQ use</b>				
≥ 6 months	1466 (73.6)	930 (75.7)	523 (70.1)	13 (76.5)
< 6 months	525 (26.4)	298 (24.3)	223 (29.9)	4 (23.5)
<b>FQ ever used</b>				
Yes	1341(67.4)	819 (66.7)	510 (68.4)	12 (70.6)
No	650 (32.6)	409 (33.3)	236 (31.6)	5 (29.4)
<b>LZD ever used</b>				
Yes	1787 (89.8)	1149 (93.6)	622 (83.4)	16 (94.1)
No	204 (10.2)	79 (6.4)	124 (16.6)	1 (5.9)
<b>Study site</b>				
Central Asia	583 (29.3)	373 (30.4)	206 (27.6)	4 (23.5)
East or Southeast Asia	94 (4.7)	27 (2.2)	64 (8.6)	3 (17.6)
South Asia	455 (22.9)	280 (22.8)	170 (22.8)	5 (29.4)
Western Asia	276 (13.9)	217 (17.7)	56 (7.5)	3 (17.6)
Europe	82 (4.1)	65 (5.3)	17 (2.3)	0 (0.0)
Sub-Saharan Africa	264 (13.3)	54 (4.4)	208 (25.9)	2 (11.8)
South America/Caribbean	237 (11.9)	212 (17.3)	25 (3.4)	0 (0.0)

551 **Table 3:** Estimated risk of recurrence overall and by HIV status under five strategies for  
 552 handling post-treatment deaths.

Strategy	Risk per 1000 <sup>1</sup>			Relative risk <sup>1</sup>
	Overall	With HIV	Without HIV	
<b>Observed recurrence</b>	6.6 (3.2, 11.2)	9.2 (2.0, 31.7)	6.3 (2.9, 10.8)	1.46 (0.31, 7.08)
<b>Hypothetical recurrence</b>	6.7 (2.8, 12.2)	9.0 (2.1, 33.5)	6.4 (2.2, 11.5)	1.42 (0.30, 7.14)
<b>Observed composite/any</b>	24.2 (14.1, 37.0)	15.6 (2.8, 42.4)	25.3 (14.6, 40.0)	0.62 (0.12, 2.01)
<b>Observed composite/probable</b>	10.5 (5.6, 16.6)	9.2 (2.1, 32.6)	10.7 (5.1, 16.7)	0.85 (0.20, 3.86)
<b>Observed composite/explicit</b>	7.8 (3.9, 13.2)	9.2 (2.1, 32.6)	7.6 (3.4, 13.1)	1.20 (0.25, 5.73)

553 <sup>1</sup>95% credible intervals are constructed as the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the 1000 bootstrap sample estimates

554  
555  
556  
557  
558

**Table 4:** Sensitivity analysis results; estimated risk of recurrence overall and by HIV status  
 under five strategies for handling post-treatment deaths, without IP-weighting to account for  
 excluded patients with missing FU data.

Strategy	Risk per 1000 <sup>1</sup>			Relative risk <sup>1</sup>
	Overall	With HIV	Without HIV	
<b>Observed recurrence</b>	7.5 (3.9, 11.2)	14.0 (4.3, 44.3)	6.6 (3.2, 11.0)	2.13 (0.64, 9.12)
<b>Hypothetical recurrence</b>	7.5 (3.1, 11.8)	13.3 (4.2, 42.0)	6.7 (2.4, 12.3)	1.99 (0.56, 10.14)
<b>Observed composite/any</b>	20.2 (13.1, 29.3)	25.9 (5.9, 65.0)	19.4 (11.8, 28.3)	1.33 (0.31, 3.47)
<b>Observed composite/probable</b>	11.9 (6.6, 18.3)	14.0 (4.4, 42.2)	11.7 (5.8, 17.8)	1.20 (0.38, 4.38)
<b>Observed composite/explicit</b>	9.1 (4.8, 15.4)	14.0 (4.4, 42.2)	8.4 (3.4, 14.3)	1.66 (0.47, 6.63)

559 <sup>1</sup>95% credible intervals are constructed as the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the 1000 bootstrap sample estimates